Tailor Bio

Executive Summary

Tailor Bio is a UK-based biotechnology company founded in 2021, headquartered in Cambridge, focused on developing targeted small molecule therapies for cancers characterized by chromosomal instability (CIN). The company aims to exploit the vulnerabilities of CIN, a common hallmark of many aggressive tumors, to create precision oncology treatments. By selectively targeting the specific dependencies that arise from chromosomal instability, Tailor Bio's platform has the potential to address a wide range of cancers with high unmet medical need. Despite being in the early stages of development, the company's innovative approach and strong scientific foundation position it as a promising player in the precision oncology space. As a private, early-stage biotech, Tailor Bio has not disclosed any funding rounds or valuation, nor does it have any public pipelines or clinical-stage assets. The company's progress is likely driven by preclinical validation and potential partnerships. The conviction score is moderate, reflecting the inherent risk of early-stage drug discovery but acknowledging the scientific rationale behind targeting CIN. Key upcoming catalysts could include preclinical data readouts, securing series A financing, or forming academic or industry collaborations to advance its therapeutic programs.

Upcoming Catalysts (preview)

• Q2 2026Series A Financing Announcement60% success
• Q4 2026Preclinical Proof-of-Concept Data in CIN Cancer Models50% success
• Q3 2026Research Collaboration with Academic or Pharma Partner40% success